By Jennifer Chiou
New York, Aug. 15 - Regado Biosciences, Inc. announced it completed $20 million in series B financing.
Domain Associates and Quaker BioVentures co-led investors, which included Aurora Funds and others.
The company also said Jesse Treu, general partner of Domain Associates, and P. Sherrill Neff, managing partner of Quaker BioVentures, have joined its board.
"The Regado drug-antidote technology is truly novel," Treu said in a news release, "and the company's initial program has the ability to transform anticoagulant therapy."
Based in Research Triangle Park, N.C., Regado is a drug development company focused on the development of antidote-controlled antithrombotics. The company is a spin-off of the Duke University Medical Center department of surgery.
| Issuer: | Regado Biosciences, Inc.
|
| Issue: | Preferred stock
|
| Amount: | $20 million
|
| Round: | Series B
|
| Investors: | Domain Associates, Quaker BioVentures (co-leads); Aurora Funds
|
| Announcement date: | Aug. 15
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
